Diagnosis and Treatment > Signs and Symptoms
Search for other papers by Diana Catarino in
Google Scholar
PubMed
Search for other papers by Cristina Ribeiro in
Google Scholar
PubMed
Search for other papers by Leonor Gomes in
Google Scholar
PubMed
Search for other papers by Isabel Paiva in
Google Scholar
PubMed
Summary
Pituitary infections, particularly with fungus, are rare disorders that usually occur in immunocompromised patients. Cushing’s syndrome predisposes patients to infectious diseases due to their immunosuppression status. We report the case of a 55-year-old woman, working as a poultry farmer, who developed intense headache, palpebral ptosis, anisocoria, prostration and psychomotor agitation 9 months after initial diabetes mellitus diagnosis. Cranioencephalic CT scan showed a pituitary lesion with bleeding, suggesting pituitary apoplexy. Patient underwent transsphenoidal surgery and the neuropathologic study indicated a corticotroph adenoma with apoplexy and fungal infection. Patient had no preoperative Cushing’s syndrome diagnosis. She was evaluated by a multidisciplinary team who decided not to administer anti-fungal treatment. The reported case shows a rare association between a corticotroph adenoma and a pituitary fungal infection. The possible contributing factors were hypercortisolism, uncontrolled diabetes and professional activity. Transsphenoidal surgery is advocated in these infections; however, anti-fungal therapy is still controversial.
Learning points:
-
Pituitary infections are rare disorders caused by bacterial, viral, fungal and parasitic infections.
-
Pituitary fungal infections usually occur in immunocompromised patients.
-
Cushing’s syndrome, as immunosuppression factor, predisposes patients to infectious diseases, including fungal infections.
-
Diagnosis of pituitary fungal infection is often achieved during histopathological investigation.
-
Treatment with systemic anti-fungal drugs is controversial.
-
Endocrine evaluation is recommended at the time of initial presentation of pituitary manifestations.
Search for other papers by Lisa Burback in
Google Scholar
PubMed
Summary
A previously healthy 32-year-old woman developed cyclical mood swings after being prescribed cabergoline for a pituitary microprolactinoma. These mood swings persisted for over 2 years, at which point she developed an acute manic episode with psychotic features and was admitted to a psychiatry unit. Cabergoline was discontinued and replaced with aripiprazole 10 mg/day. Her manic episode quickly resolved, and she was discharged within 6 days of admission. The aripiprazole suppressed her prolactin levels for over 18 months of follow-up, even after the dose was lowered to 2 mg/day. There was no significant change in tumor size over 15 months, treatment was well tolerated. However, after 9 months of taking 2 mg aripiprazole, she developed brief manic symptoms, and the dose was returned to 10 mg daily, with good effect.
Learning points
-
Dopamine agonists such as cabergoline, which are a standard treatment for microprolactinomas, can have serious adverse effects such as psychosis or valvular heart disease.
-
Aripiprazole is a well-tolerated atypical antipsychotic that, unlike other antipsychotics, is a partial dopamine agonist capable of suppressing prolactin levels.
-
Adjunctive, low-dose aripiprazole has been utilized to reverse risperidone-induced hyperprolactinemia.
-
This case report demonstrates how aripiprazole monotherapy, in doses ranging from 2 to 10 mg/day, was effective in suppressing prolactin in a woman with a microprolactinoma who developed psychiatric side effects from cabergoline.
